Moneycontrol
    Moneycontrol PRO

    Jump to

    • Interview: How Cipla plans to bounce back after a weak Q2

    • Revenue is a challenge for us; little concerned about revenue growth: Cipla

    • US, India will continue to outperform going ahead: Cipla

    • See limited competition for Pulmicort; expect 3-4 more approvals by FY18-end: Cipla

    • Will continue to pursue inorganic growth in India & US: Torrent Pharma

    • New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

    • Targeting 15% growth for FY18, export will pick up sizeably: Omkar Speciality

    • Expect to see 18-20% growth for FY18: TCI Express

    • Cipla to remain unfazed by Trump's protectionist policy

    • Looking for bigger partnership with Cipla: Serum Institute

    • Expect 10-15 launches in the US this year: Cipla

    • Indian pharma cos need to step-up safeguards at plants: Handa

    • 20% of Cipla FY17 revenues to come from US: Chirag Talati

    • Cipla completes acquisition of US cos InvaGen and Exelan

    • Sub-license for Hepatitis C drug beneficial for patients: Cipla

    • Cipla to pay for InvaGen, Exelan mostly through own funds

    • Aiming to achieve 70-80% organic growth: Cipla

    • Consumer health mkt growing at high double digit: Cipla

    • See Rs 400cr increase in top line over next few yrs: Hetero

    • What a potential Cipla-Serum merger could mean

    • Serum Institute in 'initial talks' to explore Cipla merger

    • Sun's margins may reduce to 30-32% post merger: Surajit Pal

    • Discussing partnerships, have done in-licensing deals:Cipla

    • Aiming growth of USD 3-4 bn by 2020: Cipla

    • FY15 capex Rs 400 cr, aiming for 20% EBITDA growth: Cipla

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347